ALLO supply chain intelligence for Allogene Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Allogene Therapeutics, Inc. (ALLO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| PFE | Pfizer Inc. | 92% | In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to which the Company acquired certain assets and assumed certain liabilities from Pfizer |
| PFE | Pfizer Inc. | 92% | Reciprocal relationship from PFE graph: Reciprocal relationship from ALLO graph: In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to… |
| CLLS | Cellectis S.A. | 90% | Reciprocal relationship from CLLS graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from CLLS g… |
| CLLS | Cellectis S.A. | 90% | the Company acquired certain assets and assumed certain liabilities from Pfizer, including agreements with Cellectis S.A. (Cellectis) |
| GOLDMAN-SACHS-CO-LLC | GOLDMAN-SACHS-CO-LLC | 90% | On April 14, 2026, we entered into an underwriting agreement with Goldman Sachs & Co. LLC, Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (col… |
| JEFFERIES-LLC | JEFFERIES-LLC | 90% | On April 14, 2026, we entered into an underwriting agreement with Goldman Sachs & Co. LLC, Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (col… |
| SERVIER | SERVIER | 90% | the Company acquired certain assets and assumed certain liabilities from Pfizer, including agreements with Cellectis S.A. (Cellectis) and Servier |
| TD-SECURITIES-U-S-A-LLC | TD-SECURITIES-U-S-A-LLC | 90% | In connection with the Company’s proposed public offering, the Company has suspended the offering of any shares of its common stock pursuant to the sales agreement prospectus, dated April 25, 2024, c… |
| TD-SECURITIES-USA-LLC | TD-SECURITIES-USA-LLC | 90% | On April 14, 2026, we entered into an underwriting agreement with Goldman Sachs & Co. LLC, Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (col… |
| ARTV | Artiva Biotherapeutics, Inc. | 72% | Reciprocal relationship from ARTV graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from ARTV graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from ARTV g… |
| CELU | Celularity Inc. | 72% | Reciprocal relationship from CELU graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demo… |
| CELUW | CELUW | 72% | Reciprocal relationship from CELUW graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the dem… |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or c… |
| FATE | Fate Therapeutics, Inc. | 72% | Reciprocal relationship from FATE graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of th… |
| GDTC | CytoMed Therapeutics Limited | 72% | Reciprocal relationship from GDTC graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from GDTC g… |
| INAB | IN8bio, Inc. | 72% | Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye… |
| LEGN | Legend Biotech Corporation | 72% | Reciprocal relationship from LEGN graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from LEGN g… |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from NTLA g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| OVERLAND-THERAPEUTICS-INC | OVERLAND-THERAPEUTICS-INC | 90% | Under the License Agreement, the Company received an upfront payment $40.0 million and non-cash consideration of $79.0 million in the form of shares of series seed preferred stock of Overland |
| OVERLAND-THERAPEUTICS-SH-CO-LTD | OVERLAND-THERAPEUTICS-SH-CO-LTD | 90% | Under the License Agreement, the Company received an upfront payment $40.0 million and non-cash consideration of $79.0 million in the form of shares of series seed preferred stock of Overland |
| ARTV | Artiva Biotherapeutics, Inc. | 72% | Reciprocal relationship from ARTV graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from ARTV graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from ARTV g… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from ALLO graph: y suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect dow… |
| AZN | AstraZeneca PLC | 72% | y suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies … |
| CELU | Celularity Inc. | 72% | Reciprocal relationship from CELU graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from CELU graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from CELU g… |
| CELUW | CELUW | 72% | Reciprocal relationship from CELUW graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from CELUW graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from CELU… |
| CLLS | Cellectis S.A. | 72% | is equal to nine times the total amount awarded and paid to the Company. After completing the CIRM funded research project and at any time after the award period end date (but no later than the ten-y… |
| CLLS | Cellectis S.A. | 72% | Reciprocal relationship from CLLS graph: Reciprocal relationship from ALLO graph: is equal to nine times the total amount awarded and paid to the Company. After completing the CIRM funded research pr… |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from CRBU g… |
| FATE | Fate Therapeutics, Inc. | 72% | Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely… |
| GDTC | CytoMed Therapeutics Limited | 72% | Reciprocal relationship from GDTC graph: ign or implementation of our pre-clinical studies and clinical trials; ● changes in regulatory requirements or guidance that may require us to amend or submit… |
| INAB | IN8bio, Inc. | 72% | Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye… |
| JPM-PD | JPMorgan Chase & Co. | 72% | to business disruptions, including those caused by earthquakes, power shortages, telecommunications failures, cybersecurity attacks, water shortages, floods, hurricanes, tsunamis, typhoons, fires, ex… |
| JPM-PD | JPMorgan Chase & Co. | 72% | Reciprocal relationship from JPM-PD graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from JPM-PD graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from JP… |
| LEGN | Legend Biotech Corporation | 72% | Reciprocal relationship from LEGN graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from LEGN g… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from ALLO graph: y suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect do… |
| MYGN | Myriad Genetics, Inc. | 72% | y suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies … |
| TCRX | TScan Therapeutics, Inc. | 72% | Reciprocal relationship from TCRX graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from TCRX graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from TCRX g… |
| FBIO | Fortress Biotech, Inc. | 62% | Reciprocal relationship from FBIO graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from FBIO graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from FBIO g… |
| LIFE | LIFE | 62% | Reciprocal relationship from LIFE graph: Reciprocal relationship from ALLO graph: is equal to nine times the total amount awarded and paid to the Company. After completing the CIRM funded research pr… |
| LIFE-TECHNOLOGIES-CORPORATION | LIFE-TECHNOLOGIES-CORPORATION | 62% | is equal to nine times the total amount awarded and paid to the Company. After completing the CIRM funded research project and at any time after the award period end date (but no later than the ten-y… |
| SI | Shoulder Innovations, Inc. | 62% | Reciprocal relationship from SI graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from SI graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from SI graph: … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ALLO-DEBT-7684 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-12-31. |
| ALLO-DEBT | Debt stack $81.1M | 90% | Market cache reports total debt of $81.1M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ALLO-OWNER-PFIZER-INC | Pfizer Inc | 90% | 13F overlay lists Pfizer Inc as top holder; 208 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| MYGN | Myriad Genetics, Inc. | 100.00 | 1 | ['customer'] |
| CLLS | Cellectis S.A. | 100.00 | 1 | ['customer', 'supplier'] |
| INAB | IN8bio, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| JPM-PD | JPMorgan Chase & Co. | 100.00 | 1 | ['customer'] |
| NTLA | Intellia Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| CELU | Celularity Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ARTV | Artiva Biotherapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| GDTC | CytoMed Therapeutics Limited | 100.00 | 1 | ['customer', 'supplier'] |
| LIFE | Ethos Technologies Inc. | 100.00 | 1 | ['customer'] |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CELUW | Celularity Inc | 100.00 | 1 | ['customer', 'supplier'] |
| TCRX | TScan Therapeutics, Inc. | 100.00 | 1 | ['customer'] |
| PFE | Pfizer Inc. | 100.00 | 1 | ['supplier'] |
| SI | Shoulder Innovations, Inc. | 100.00 | 1 | ['customer'] |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['customer'] |
| FATE | Fate Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| DLR-PJ | DIGITAL REALTY TRUST, INC. | 50.00 | 2 | |
| CAN | Canaan Inc. | 50.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 50.00 | 2 | |
| BNBX | BNB Plus Corp. | 50.00 | 2 |